ⓘ Cantuzumab

                                     

ⓘ Cantuzumab

Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen.

It is usually associated with one of several cytotoxic agents, obtaining antibody-drug conjugates:

  • Cantuzumab mertansine.
  • Cantuzumab ravtansine.
                                     
  • Cantuzumab mertansine SB - 408075 huC242 - DM1 is an antibody - drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a
  • Cantuzumab ravtansine huC242 - SPDB - DM4 is an antibody - drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab
  • this design include trastuzumab emtansine, lorvotuzumab mertansine, and cantuzumab mertansine. Some are still experimental others are in regular clinical
  • canrenoic acid INN canrenone INN Cantharone Cantil cantuzumab mertansine INN cantuzumab ravtansine USAN, INN Cap - Profen capadenoson INN Capastat
  • Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK January 2003 Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen:
  • Calreticulin Cancer immunology Cancer immunoprevention Cancer immunotherapy Cantuzumab ravtansine Cathelicidin CC chemokine receptors CCBP2 CCL1 CCL11 CCL12